Operating Expenses
Acquired in-process research and development
Gilead Sciences Acquired in-process research and development increased by 217.6% to $540.00M in Q4 2025 compared to the prior quarter. Over 3 years (FY 2021 to FY 2025), Acquired in-process research and development shows relatively stable performance with a 2.9% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2013
Last reportedQ4 2025
How to read this metric
High levels indicate an active inorganic growth strategy, while low levels suggest a focus on internal development.
Detailed definition
This metric captures the costs associated with acquiring research and development projects from third parties that have...
Peer comparison
Common in the pharmaceutical and biotech sectors where M&A is a primary strategy for pipeline replenishment.
Metric ID:
is_lly_acquired_in_process_research_and_developmentHistorical Data
17 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $234.75M | $234.75M | $234.75M | $330.00M | $448.00M | $481.00M | $236.00M | $91.00M | $347.00M | $4.13B | $38.00M | $505.00M | $0.00 | $253.00M | $61.00M | $170.00M | $540.00M |
| QoQ Change | — | +0.0% | +0.0% | +40.6% | +35.8% | +7.4% | -50.9% | -61.4% | +281.3% | >999% | -99.1% | >999% | -100.0% | — | -75.9% | +178.7% | +217.6% |
| YoY Change | — | — | — | +40.6% | +90.8% | — | -28.5% | -79.7% | — | +758.8% | -83.9% | +454.9% | -100.0% | -93.9% | +60.5% | -66.3% | — |
Range$0.00 – $4.13B
CAGR+23.2%
Avg YoY Growth+86.7%
Median YoY Growth-28.5%
Current Streak2 quarters growth
Acquired in-process research and development at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's acquired in-process research and development?
- Gilead Sciences (GILD) reported acquired in-process research and development of $540.00M in Q4 2025.
- What is the long-term trend for Gilead Sciences's acquired in-process research and development?
- Over 3 years (2021 to 2025), Gilead Sciences's acquired in-process research and development has grown at a 2.9% compound annual growth rate (CAGR), from $939.00M to $1.02B.
- What does acquired in-process research and development mean?
- Costs paid to acquire unfinished research projects from other companies.